

Original Research Article

Validation of decision cut off values of serum albumin and prothrombin time for differentiating between compensated and decompensated liver cirrhosis.

ABSTRACT:

Aims: Serum bilirubin, albumin and prothrombin time are the most commonly measured parameters to assess the progress of hepatic cirrhosis. No widely accepted cut off values for these parameters are available for an early diagnosis of the decompensation process of hepatic cirrhosis. We aimed to establish the cut off values for these parameters with maximum sensitivity and minimum false positivity between 30 decompensated and 33 compensated cirrhosis patients through ROC curves for making a medical decision at the earliest.

Study design: It was a hospital based, cross sectional, observational study. Both of the case and control groups were selected by the method of convenience.

Place and Duration of Study: Study subjects were analyzed in the Department of Medicine (Medical Unit II), Department of Biochemistry and Department of Radiology, Mamata Medical College, Khammam, Andhra Pradesh, India between Jan 2009 and Feb 2010.

Methodology:

Sample: 63 patients (40 men, 23 women; age range 20-60 years) diagnosed as hepatic cirrhosis on the basis of clinical, biochemical and ultrasonographic features were included as the case group in the study. 35 age and sex matched normal healthy subjects were included in the control group. Patients with portal hypertension, ascitis, encephalopathy and with the medical history of gastrointestinal bleeding, were put in the decompensated group (n =30). Cases without the above criteria were selected in the compensated group (n =33).

Results:

Cirrhosis patients showed significant increase in serum bilirubin level (6.79/2.19 vs 0.86/0.02, $p < 0.001$) and prothormbin time (20.13 +/- 2.25 vs 15.54 +/- 0.63, $P < 0.001$) with opposite trend with serum albumin (3.05 +/- 0.62 vs 3.69 +/- 0.83, $p < 0.001$) when compared to normal control group. Furthermore, the decompensated group showed a significant rise in serum bilirubin (8.90 +/- 0.78 vs 4.80 +/- 0.79, $p < 0.001$) and prothrombin time (21.44 +/- 2.5 vs 18.93 +/- 0.84, $p < 0.001$) with a decrease of serum albumin (2.8 +/- 0.36 vs 3.2 +/- 0.76, $p < 0.027$) in comparision to compensated group. ROC analysis for the serum albumin level and prothrmbin time between the compensated and decompensated groups showed their cut off values to be 2.97g/dl and 19.47 seconds

respectively. No cut off value for serum bilirubin could be obtained due to non overlapping values between the two groups.

Conclusion:

The calculated cut off values of serum albumin and prothrombin time in our study indicate the transition phase between the compensatory and decompensatory groups of hepatic cirrhosis. As early detection of the decompensation process can guide the clinicians to take the proper management to reduce the complications and mortality significantly, these cut off values should provide useful diagnostic and therapeutic tools in these patients.

Keywords: Cirrhosis, Decompensation, Medical decision values, Albumin, Prothrombin time.

INTRODUCTION (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

In cirrhosis of liver presence of either of the jaundice, ascitis, portal hypertensive gastrointestinal bleeding or hepatic encephalopathy together, or in isolation, is considered as a decompensated state in the disease process. These manifestations appear when the disease process supersedes the compensatory mechanisms, either by progression of the disease or a superimposed acute insult. Clinically and biochemically the transition from well compensated cirrhosis to symptomatic decompensation is gradual and in subtle stages without any clear demarcating points. However, decompensation per se, increases the risk of mortality significantly. One year mortality in compensated cirrhosis is 1-3.4%, that in decompensated state is reported to be as high as 20-57% [1]. Moreover, decompensated cirrhosis can also lead to hepatocellular carcinoma that increases the mortality rate in these patients significantly [2]. Biochemical parameters play important roles for monitoring the transition state from compensation to decompensation. Increased serum bilirubin was observed by some authors in compensated cirrhosis with a more significant increase in its decompensated state[3]. Protein energy malnutrition (PEM), in many cirrhosis patients[4] is also more pronounced, in decompensated state [5]. PEM is associated with a high mortality and morbidity due to increased risk of life threatening complications resulting in poor survival and poor quality of life [6,7]. Serum albumin level have been reported to serve as an important indicator of the severity of liver cirrhosis and an improvement of its level is vital for improving the prognosis of the disease. It has been reported that the serum albumin level have decreased at a rate of 0.15 gm/dl per year in patients with liver cirrhosis [8]. Some authors assume that serum albumin level above an approximate threshold of 3.5 gm/dl, might indicate transition to decompensated cirrhosis. Sato et al found that improving or maintaining serum albumin prevented the onset of hepatic encephalopathy [9], which is the hallmark of decompensated cirrhosis. Oral supplementation with branched chain amino acid (BCAA) preparations have been reported to improve event free survival and quality of life by raising serum albumin concentrations in patients with decompensated cirrhosis[10]. These findings were strengthened by some observations that suggested a reduction in ascitis in hepatic cirrhosis after BCAA supplementation [11]. On the other hand, a significantly increased prothrombin time (PT) was also found in patients with chronic liver disease in comparison to controls with a significant increase in acute variceal bleeding induced mortality that ranges from 0.5% to 50% in patients with liver cirrhosis [12]. Recombinant factor vii may be useful in variceal bleeding as it has been shown to normalize pt and bleeding time (BT) in cirrhosis [13]. Some authors also documented hyperfibrinolytic activity and abnormal PT in cirrhosis patients [14]. Furthermore, a correlation was found between reduced level of factor ii,vii, ix, x in liver cirrhosis with its severity [15]. Keeping in track, the model for end stage liver disease scoring system(meld) has put a strong emphasis on international normalized ratio (INR) [16] for assessing the role of clotting factors in the decompensation process. Previously, Kato et al identified the characteristics of decompensated cirrhosis and suggested the proper time to begin the administration of BCAA granules preparation at an albumin level lower than 3.5g/dl and the prothrombin activity lesser than 60% [17]. Although, most of the studies reported a significantly raised serum bilirubin level and prothrombin time along with a reduction in serum albumin level during the process of decompensation, we could not find any study regarding the cut off value of serum bilirubin that could demarcate the decompensated hepatic cirrhosis from the compensated ones. Similarly, not many studies could report a clear cut medical decision limits for serum albumin and PT in these patients and importantly, when any such cut off values were reported, they varied significantly region wise [8,17,18]. Furthermore, some investigators evaluated definite values of different biochemical parameters obtained either as distinctive cut off values or ratios that could predict the severity of disease throughout its pathological process and thus, identify the transition process between compensation and decompensation states with a much more clarity [8,19]. In our region also, we could find few evidences, so far, regarding the blood levels of common biochemical parameters which could substantiate the disease progression from compensated to decompensated state in the hepatic cirrhosis patients. So, in the present study, we assessed the serum bilirubin, albumin and PT in compensated and decompensated cirrhosis patients, and made an effort to establish a cut off value of these parameters between the two disease groups that could at least biochemically differentiate between the compensated and

decompensated states and help in initiation of proper treatment or management at the most appropriate stage reducing the mortality in cirrhosis patients.

2. MATERIAL AND METHODS / EXPERIMENTAL DETAILS / METHODOLOGY (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

2.1. Study design:

This hospital based, cross sectional and observational study was conducted in the Department of Biochemistry, Mamata Medical College and Hospital, Khammam, Andhra Pradesh, India.

2.2. Selection of study subjects:

63 patients of liver cirrhosis (compensated-M=22, F=11.decompensated-M=18, F=12) with the age group of 20 to 60 years were selected for study from Outdoor Patient Department(OPD) and Indoor wards on convenience basis. Diagnosis of liver cirrhosis was done from detailed history, clinical and radiological examination as well as ultrasonography of liver and from relevant biochemical tests. 35 age matched, healthy subjects(not addicted to smoking,alcohol or drugs) were selected as the control group from the students, hospital staffs and persons accompanying the patients.

2.2.1.Exclusion criteria:

Cases: Liver cirrhosis patients associated with concomitant pathology like diabetes mellitus, hypertension, chronic diarrhoea, renal failure, infective hepatitis and obstructive liver disease or taking drugs causing alteration of serum albumin or prothrombin time were excluded from the study. Severely ill like shock, acidosis, alkalosis, hypoglycemia, unconscious, disabled and non cooperative patients were also excluded from the study.

Controls: persons with history of any type of hepatitis, alcohol addiction, habituated smoking behaviour and recent history of any drug intake capable of altering liver function were not included in the control population for this study.

All study subjects were from the same geographical area with no significant difference in their food habit and drinking water quality.

2.2.2. Ethical consideration:

Written consents were obtained from the participants (case and control groups). The study followed the Helsinki declaration for human studies, 1975 and was undertaken after obtaining the ethical clearance from the institutional ethical committee.

2.2.3. Classification of subjects into study groups:

Normal control subjects were considered as **Group 1(n=35)**. Liver cirrhosis patients with ascites, portal hypertensive gastrointestinal bleeding, and encephalopathy were considered in decompensated group or **Group 3(n=30)**. Liver cirrhosis patients without the above mentioned features were considered in compensated group or **Group 2(n=33)**.

2.3. Measurement of study parameters:

2.3.1.Sample collection:

Blood was obtained from patients and controls after an overnight fast. The blood was drawn into plastic syringes fitted with stainless steel needles, immediately transferred to metal free tubes, allowed to clot, centrifuged, and serum removed to another metal free tube for storage at -20^o until assayed.

2.3.2. Methods of measurement of analytes:

Serum bilirubin was estimated by modified Jendrassik & Grofs Method (Crest Biosystems) [20]. Albumin was estimated by Bromocresol green (BCG) dye binding method from Crest Biosystems, India in the XL 600 autoanalyser from Erba Transasia [21]. Prothrombin time was estimated by Quick's method using coagulometer from Erba Transasia, USA [22]. All assays were done in duplicate and average values were taken. Coefficient of variation (CV) for the control samples (level 1 and 2 from Lypocheck, Biorad, USA) for the study parameters remained below 5% throughout the study period.

2.4. Statistical analysis:

Statistical analysis was aimed to 1) assess the difference between the mean values of serum bilirubin, albumin and prothrombin time between the case (both group 2 and 3) and control groups, 2) assess the difference between the mean values of serum bilirubin, albumin and prothrombin time between the two case groups (group 2 and 3), and 3) obtain the cut off values for serum bilirubin, albumin and PT between the two case groups at the maximum level of sensitivity versus minimum false positivity by the receiver operator characteristic curve (ROC). All analyses were done with the help of SPSS software version 17.0 for Windows.

3. RESULTS:

Table I : Independent t test to show the difference between the mean values of serum albumin and prothrombin time in liver cirrhosis patients (for both groups I and II, N = 63) and control subjects (N = 35):

	Liver cirrhosis patients in both groups (N = 63)	Control subjects (N = 35)	t value	Significance (p value)
Serum Albumin in g/dL (Mean +/-SD)	3.05 +/- (0.62)	3.69 +/- (0.83)	-4.2	P < 0.001
Prothrombin time in secs. (Mean +/-SD)	20.13 +/- (2.25)	15.54 +/- (0.63)	11.7	P < 0.001
Serum bilirubin level in mg/dl	6.75 +/- (2.19)	0.86 +/- (0.02)	15.8	P<0.001

*p value significant at the level of p < 0.05 at 95% confidence interval

It is evident from the Table I that serum albumin level is significantly decreased and the serum bilirubin and prothrombin time is significantly raised in liver cirrhosis patients in comparison to the control subjects.

Table II : Independent t test to show the difference between the mean values of serum albumin and prothrombin time in compensated (N = 33) and decompensated (N = 30) liver cirrhosis patients:


	Compensated liver cirrhosis(n=33)	Decompensated liver cirrhosis(n=30)	t value	Significance (p value)
Serum Albumin in g/dL (Mean +/-SD)	3.2 +/- (0.76)	2.8 +/- (0.36)	2.26	*p = 0.027
Prothrombin time in secs. (Mean +/-SD)	18.93 +/- (0.84)	21.44 +/- (2.5)	-5.29	*p < 0.001
Serum bilirubin in mg/dl	4.80 +/- (0.79)	8.90 +/- (0.68)	-21.7	*p < 0.001

*p value significant at the level of p < 0.05 at 95% confidence interval

Results in the Table II reveals a significantly reduced level of serum albumin in the decompensated liver cirrhosis patients. On the other hand, serum bilirubin and prothrombin time is found to be significantly increased in the decompensated group.

To find out the critical value of both parameters beyond which these parameters fall into decompensated group we carried out ROC analysis for these parameters against a specific sensitivity and false positivity. According to the established rules we obtained these cut off points from the left uppermost corners of the ROC curves (encircled points in Fig. 1 & 2) that suggested the cut off values with highest sensitivity with lowest false positivity (1-specificity).


Figure 1: ROC for showing the cut off value of serum albumin between compensated and uncompensated groups of liver cirrhosis.



Diagonal segments are produced by ties.

ROC curve in figure 1 shows the critical value of serum albumin between decompensated and compensated group of liver cirrhosis to be 2.97 g/dl, with a sensitivity of 0.67 and false positivity of 0.40 with an area under curve of 0.690. It indicates that decompensation process in hepatic cirrhosis is closely associated with a serum albumin level below 2.97g/dl.

Figure 2: ROC for showing the cut off value of serum prothrombin value and serum bilirubin level between compensated and decompensated groups of liver cirrhosis.



Diagonal segments are produced by ties.

On the other hand ROC curve in figure 2 shows the cut off value for PT to be 19.47 seconds with a sensitivity 0.8 and false positivity of 0.24 with an area under curve of 0.82, that indicates the close link between decompensation process to a prothrombin value greater than 19.47 seconds. On the other hand, no overlapping value and hence cut off values are observed with an area under curve for serum bilirubin being 1.

4. DISCUSSION

Decompensation per se, is a significant risk of mortality and malignancy in cirrhosis of liver [1]. Biochemical parameters are more practicable for differentiation between the decompensated and compensated phases as definitive histopathological tissue examination is not always possible in these cases. In our present study we made an effort to utilise three common and easily measurable parameters like serum bilirubin, albumin and prothrombin time as such biochemical parameters for an early detection of the decompensation state and hence a more favourable outcome due to an earlier intervention.

In our study, Table I have shown that the mean serum bilirubin level is increased, albumin level is reduced, and mean prothrombin time is prolonged significantly in liver cirrhosis patients than controls. All of these parameters showed similar deviations in the decompensated group as compared to the compensated hepatic cirrhosis (Table II).

Koruk M et al found the mean serum bilirubin level is 2.19 mg/dl in decompensated liver cirrhosis and 1.14 mg/dl in compensated one [3]. Those observations were strengthened by Villeneuve JP et al [23] who observed the serum bilirubin level was 3.9 mg/dl in decompensated liver cirrhosis. The findings of those studies keep in tract with our observations where we found serum bilirubin level is 8.9 mg/dl in decompensated and 4.8 mg/dl in compensated liver cirrhosis.

Our major aim in this study was to find out a cut off value for these three common parameters that could demarcate the decompensation process at the earliest. For this we undertook the ROC analysis for these parameters in both compensated and decompensated groups and determined the cut off value on the basis of maximum sensitivity and minimum false positivity among the overlaps . Serum bilirubin level could not yield such a cut off point from the ROC (broken lines in figure 2) as there was no overlapping value between the two groups. This observation suggests that the increase in bilirubin during the process of decompensation occurs abruptly and there was no smooth and continuous deterioration in its detoxification process during the decompensation process. Hence, it can be suggested that the failure in detoxification process by the hepatocytes occurs much rapidly as the cirrhosis patients transit to decompensated state

from a compensated condition. Studies have reported strong evidences of a deterioration in alternative pathways of detoxification along with the classical pathways of glucuronidation of bilirubin in cirrhotic livers that may explain the sharp rise in bilirubin level during decompensation [24]. Hence, in our study we were not able to get any critical value of serum bilirubin between compensated and decompensated groups since there was no overlapping of values between the two disease groups.

However, hepatic functions related to synthesis of albumin and prothrombin did not follow this pattern as they showed a relatively smoother and gradual deterioration during the process of decompensation yielding several overlapping values in both group I and II patients. In the present study, ROC curves in figure 1 and figure 2 showed cut off values of serum albumin and PT that can differentiate between the compensated and decompensated liver cirrhosis with the maximum possible sensitivity and minimum possible false positivity. These cut off values can be considered as the critical values for these study parameters for making appropriate medical decisions. In our study such critical values of serum albumin and PT between the compensated and decompensated group of liver cirrhosis has been found to be 2.97 g/dl and 19.47 seconds respectively (Fig. 1 & 2). Based on these results we suggest that in liver cirrhosis a reduction of serum albumin level below 2.97 g/dl, indicates the initiation of the process of decompensation. Similarly, with a PT value more than 19.47 seconds features of decompensation and bleeding disorders related to complicated cirrhosis start appearing. The findings of our present study can be explained through the observations found by Kiammt S et al who described a decrease in albumin binding capacity in patients with decompensated liver cirrhosis which correlated inversely with severity of disease [25]. Some authors utilized serum albumin and PT or INR (the ratio of PT of cases to PT of controls) for prediction of the severity of liver cirrhosis [26]. In agreement with these studies we observed that the serum albumin was not only significantly decreased in decompensated liver cirrhosis patients in comparison to controls and compensated liver cirrhosis patients, but more importantly, to a lesser level than observed in other studies (Table I & II). Serum albumin level is not only an indicator of the synthetic function of the liver, maintenance of its optimum level is also necessary for regulating normal trace element homeostasis in our body. Zinc is transported in plasma mostly by albumin (60-70%) [27]. Hence, a lowered serum albumin level results in a reduced zinc level in body that might be responsible for an increased risk of hepatic encephalopathy and hepatocellular carcinoma observed in decompensated liver cirrhosis patients [27,28,29,30]. Low zinc level in liver cirrhosis patients might be the result of decreased liver albumin content, poor dietary intake or protein restriction [27]. Accordingly, some reports indicated that zinc supplementation may have a beneficial role in decompensated liver cirrhosis patients with hepatic encephalopathy, but further trials are necessary to have conclusive evidence [30,31]. Sato et al suggested that maintaining serum albumin prevented the onset of hepatic encephalopathy [9].

The importance of evaluating the critical value of albumin is evident from the delay in the process of decompensation after administration of effective therapy at this juncture. Some authors documented that the oral supplementation with BCAA preparation improves event free survival, serum albumin concentration and quality of life in decompensated cirrhosis [10]. BCAA also reduced ascitis in decompensated liver cirrhosis [11]. Several authors tried to establish the proper time to begin the administration of BCAA supplementation. Serum albumin level ≤ 3.5 g/dl was suggested by some authors [12]. Studies also noticed that serum albumin level decreases at a rate of 1.5 g/L per year in patients with liver cirrhosis and a level below 35 g/L might indicate the transition to decompensated liver cirrhosis [8]. So the appropriate time for BCAA administration becomes vital for therapeutic purpose in decompensated liver cirrhosis along with prevention of related complications.

These observations prompted us to search for a new cut off value for this parameter in our region considering the fact that albumin has got major biochemical role as a marker for several crucial hepatic functions. The results of our study indicate that appropriate time at which the BCAA as well as the zinc preparations can be started might be 2.97 g/dL which is slightly lower than those found in some other studies in different regions of world. However, we could not find similar studies in India. We suggest that different contributory factors like routine dietary habits, environmental status and genetic make up may play important role in this slightly lower critical value of serum albumin in our region.

Blood coagulation factors apart from factor VIII are all produced by hepatocytes. Their serum half lives are much shorter than that of albumin. Owing to their rapid degradation, the measurement of coagulation factors is one of the best indicators of liver synthetic function, and is beneficial for assessing severity and following progress of liver disease [18]. Several authors have described strong relationship between cirrhosis of liver and the compromised status of clotting factors along with a strong correlation between decreased levels of factor II, V, VII, IX, and X and the severity of liver diseases [15]. The modified Child Pugh stated PT > 11 seconds or albumin < 2.3 g/dl for identification of severely decompensated liver cirrhosis [28]. Some authors strengthened the prognostic importance of PT in cirrhosis of liver by pointing out the optimal time to initiate treatment with BCAA at a prothrombin activity of $\leq 60\%$ [12].

Keeping all these factors in mind we tried to establish a cut off value of PT in our study population following determination of the same for serum albumin. Our results indicated it to be 19.47 secs. As described earlier the cut off value of serum bilirubin between compensated and decompensated group cannot be determined since the bilirubin values are not

overlapping each other in two disease groups. Hence we suggest that along with an albumin level lower than 2.97 g/dl, a PT more than 19.47 seconds strongly indicate the progression of hepatic cirrhosis into its decompensated state in majority of the cases. Our study results are somehow different from the observations recorded by the modified Child Pugh [32] that stated a PT level more than 11seconds or albumin level of less than 2.3 g/dl for progression into decompensation. However, the modified Child Pugh study was carried in severely decompensated liver cirrhosis patients. Along with other contributory factors the degree of decompensation might have affected the critical values of these parameters.

Nevertheless, the above mentioned parameters have some pitfalls for assessing the severity of the disease if considered in isolation. Serum albumin being a negative acute phase reactant has been reported to be falsely decreased by IL-6 under inflammatory conditions. Furthermore, although in cirrhosis of liver the synthesis of albumin has been found to be decreased generally, normal values or an increase has been found in some cases also. Loss of albumin in ascitic fluids has been also attributed to its lowered serum value. Similarly, the proteins induced by vitamin K antagonists (PIVKA) like warfarin can elevate the PT significantly [33]. To avoid these interferences and for obtaining a more realistic state of decompensation in hepatic cirrhosis, we propose to consider that the cut off values of serum albumin and PT taken together will provide substantial help in determining the progression to decompensation at an early stage and will help the clinicians to take the appropriate steps for reducing the grave consequences of liver cirrhosis. Serum bilirubin, albumin and PT are the three simple and commonly performed parameters estimated in laboratories for liver cirrhosis patients. Finally, measurement of these simple parameters(bilirubin couldn't show cut off value) are easy to perform, cost effective and can be carried out in almost all laboratories.

Limitations of the study and implications of future research: The study was done in Mamata General Hospital, Khammam which caters rural population mainly with low socio economical status. A larger sample size including the urban population as well can reflect our goals more accurately. There is a great need of broader study on liver cirrhosis and its complications which can ultimately help in achieving the goal of healthy and prosperous society.

4. CONCLUSION

Selecting the parameters like albumin and prothrombin time for assessing the cut off values between the compensated and decompensated groups of liver cirrhosis is a more realistic approach. Furthermore, the present study strengthens the importance of these two markers taken together for assessing the initiation of decompensation process at a greater accuracy. These cut off values of albumin and prothrombin time in liver cirrhosis patients are inherent to the local study population and thus, can help the clinicians to take the appropriate step (like to start BCAA and zinc preparations) to counteract the serious consequences of the disease. These observations, in our opinion, have significant relevance to healthcare of India; as liver cirrhosis is a common occurrence in our country.

ACKNOWLEDGEMENTS

Nil.

COMPETING INTERESTS

No potential conflicts of interest including employment, consultancies, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding were involved in the present study.

AUTHORS' CONTRIBUTIONS

Dr. Kaushik Kar and Dr. Anindya Dasgupta designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Dr. Suparna Ray, Dr. Satwika Sinha and Dr. Ushasi Banerjee managed the analyses of the study. and managed the literature search. All authors read and approved the final manuscript."

CONSENT (WHERE EVER APPLICABLE)

All authors declare that 'written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal."

ETHICAL APPROVAL (WHERE EVER APPLICABLE)

All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

REFERENCES

1. Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. *Int J Hepatol* 2012;2012:318627.
2. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Jin GY, et al. Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. *AJR Am J Roentgenol*. 2006 May;186(5 Suppl):S261-268.
3. Koruk M, Aksoy H, Akcay F, Onuk MD. Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis. *Annals of clinical and laboratory science*. 2002;32(3): 252-56.
4. Tajika M, Kato M, Mohri H, Miwa Y, Kato T, Ohnishi H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. *Nutrition*. 2002 Mar;18(3):229-34.
5. Cabre E, Gassull MA. Nutritional support in liver disease. *Eur J Gastroenterol Hepatol*. 1995 Jun;7(6):528-32.
6. Nutritional status in cirrhosis. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. *J Hepatol*. 1994 Sep;21(3):317-25.
7. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein-and energy-source in liver cirrhosis. *Biochem Biophys Res Commun*. 2004 Jan 9;313(2):405-9.
8. Kobayashi M, Ikeda K, Arase Y, Suzuki Y, Suzuki F, Akuta N, et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. *J Gastroenterol*. 2008;43(1):63-70.
9. Sato S, Watanabe A, Muto Y, Suzuki K, Kato A, Moriwaki H, et al. Clinical comparison of branched-chain amino acid (L-Leucine, L-Isoleucine, L-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). *Hepatol Res*. 2005 Apr;31(4):232-240.
10. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol*. 2005 Jul;3(7):705-13.

11. Itou M, Kawaguchi T, Taniguchi E, Oku Y, Fukushima N, Ando E et al. Branched-chain amino acid supplements reduced ascites and increased the quality of life in a patient with liver cirrhosis: A case report. *Mol Med Rep*. 2009 Nov-Dec;2(6):977-81.
12. El-Sayed R, El-Karaksy H, El-Raziky M, El-Hawary M, El Koofy N, Helmy H, et al. Assessment of coagulation and fibrinolysis in children with chronic liver disease. *Blood Coagul Fibrinolysis*. 2013 Mar;24(2):113-117.
13. Patch D, Dagher L. Acute variceal bleeding: general management. *World J Gastroenterol*. 2001 Aug;7(4):466-75.
14. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. *Am J Gastroenterol*. 2001 May;96(5):1581-86.
15. Giraldez Gallego A, Sousa JM, Pascasio JM, Prats C, Cayuela A, Garrido A. Blood coagulation factor levels in candidates for liver transplantation: correlation with disease severity. *Gastroenterol Hepatol*. 2009 Aug-Sep;32(7):465-71.
16. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, et al. The international normalized ratio calibrated for cirrhosis (liver) normalizes prothrombin time results for model for end-stage liver disease calculation. *Hepatology*. 2007 Aug;46(2):520-27.
17. Kato A, Suzuki K. How to select BCAA preparations. *Hepatol Res*. 2004 Dec;30S:30-35.
18. Tsuchiya K, Asahina Y, Izumi N. Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma. *Nihon Shokakibyo Gakkai Zasshi*. 2008 Jun;105(6):808-16.
19. Livy A, Lye S, Jagdish CK, Hanis N, Sharmila V, Ler LW, et al. Evaluation of quality of DNA extracted from buccal swabs for microarray based genotyping. *Indian J Clin Biochem*. 2012 Jan;27(1):28-33.
20. Tolman KGRR. Tietz textbook of clinical chemistry. 3rd ed. In: Burtis CA, Ashwood ER, editors. Liver function. Philadelphia:W.B Saunders Company; 1999. p. 1125–77.
21. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. *Clin Chim Acta*. 1971 Jan;31(1):87-96.
22. Quick AJ. Experimentally induced changes in the prothrombin level of the blood; quantitative studies in dogs given dicumarol; the effect of methylxanthines on prothrombin per se and when administered with dicumarol. *J Biol Chem*. 1945;161:33-44.
23. Kaderlik KR, Minchin RF, Mulder GJ, et al. Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. *Carcinogenesis*. 1994;15:1703–9.
24. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. *Hepatology*. 2000 Jan;31(1):207-10.
25. Klammt S, Mitzner S, Stange J, Brinkmann B, Drewelow B, Emmrich J, et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. *Eur J Gastroenterol Hepatol*. 2007 Mar;19(3):257-63.
26. Lee HS, Kim JK, Cheong JY, Han EJ, An SY, Song JH, et al. Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis. *Korean J Hepatol*. 2010 Dec;16(4):369-75.
27. Lin CC, Huang JF, Tsai LY, Huang YL. Selenium, iron, copper, and zinc levels and copper-to-zinc ratios in serum of patients at different stages of viral hepatic diseases. *Biol Trace Elem Res*. 2006 Jan;109(1):15-24.

28. Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura SI, Watanabe A, et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. *Acta Med Okayama*. 2001 Dec;55(6):349-55.
29. Nomura F, Takekoshi K. Zinc and selenium metabolism in liver cirrhosis. *Nihon Rinsho*. 1994 Jan;52(1):165-69.
30. Chetri K, Choudhuri G. Role of trace elements in hepatic encephalopathy: zinc and manganese. *Indian J Gastroenterol*. 2003 Dec;22 Suppl 2:S28-30.
31. Capocaccia L, Merli M, Piat C, Servi R, Zullo A, Riggio O. Zinc and other trace elements in liver cirrhosis. *Ital J Gastroenterol*. 1991 Jul-Aug;23(6):386-91.
32. Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. *Liver Transpl*. 2006 Jan;12(1):65-71.
33. Dufour DR. Liver disease. In: Burtis CA, Ashwood ER, Bruns DE. (Editors). *Teitz Textbook of clinical chemistry and molecular diagnostics*. 4th ed. New Delhi: Elsevier;2006:1787-89.

APPENDIX:NIL